We further examine the potential of engineered exosomes in modulating core AD pathological pathways, including amyloid‐beta deposition, tau hyperphosphorylation, neuroinflammation and synaptic dysfunction, and highlight their utility as an integrated delivery system for the co‐delivery of multiple therapeutic agents to achieve synergistic therapeutic effects. This evidence concerns the gene MAPT and Alzheimer disease.